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Abstract
Background: Cancer therapies that kill cancer cells without affecting normal cells is the ultimate mode of treating
cancers. The VP3, an avian virus-derived protein, can specifically initiate cell death through several signal
transduction pathways leading to apoptosis. In cancer, chemoresistance and cell survivability implicate the cell
surface protein, CD147.
Methods: In this study, transfection of VP3 and silencing of CD147 genes was achieved through the treatment of
tumors with pVIVO1-GFP/VP3 (VP3), psiRNA-CD147/2 (shCD147/2), and their combination of CT26 colon cancer
cell-induced in mice. The effectiveness of tumor-treatment was ascertained by electrophoresis, TUNEL assay, and flow
cytometry analysis. While histopathological and biochemical analysis were used as toxic side effect identification.
Results: The tumor growth delay index (TGDI) after treatment with VP3, shCD147/2, and their combination treatments
increased by 1.3-, 1.2-, 2.0- and 2.3-fold respectively, over untreated control. The VP3-shCD147/2 combination
treatment was more efficacious then either VP3 or shCD147/2 alone in the retardation of mouse CT26 colorectal
cell tumor allograft.
Conclusion: The antitumor effect of the combination treatment is the result of synergistic effects of VP3 and
shCD147/2 on the tumor cells resulting in apoptosis. Thus, the study shows that combination of VP3 and
shCD147/2 treatment can be developed into a potential approach for anticolorectal cancer treatment regimen.
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Background
Colorectal cancer is the third most common cancer
cases after lung (1.82 million) and breast (1.67 million)
cancers [1]. Within the next 15 years approximately 1.4
million new cases of colorectal cancer are expected to
occur with an estimated death of 693 000 that would ac-
count for 8.5 % of all cancer deaths [2]. Poor survival
rate of colon cancer patient is partly due to poor under-
standing of the disease and its progression, invasion, mi-
gration and metastasis [3].
Basigin/CD147, a transmembrane glycoprotein of the
immunoglobulin superfamily, is expressed widely on
many cell types and highly expressed in various tumor
cells [4]. CD147 play an important role in proliferation,
angiogenesis, invasiveness and metastatic activity of ma-
lignant melanoma [5]. Increased expression of CD147
was shown to correlate with enhanced tumor progres-
sion and poor prognosis in different cancers [6–8]. Thus,
an attractive way to curb tumor progression is through
suppression of the CD147-dependent cell proliferation,
invasion and metastasis by RNAi-mediated silencing [5, 9]
and eventually induce cell apoptosis due to detachment of
anchorage-dependent cell from the surrounding extracel-
lular matrix [10, 11].
In the development of anti-cancer compounds, apop-
tosis is the preferred mode of cancer cell death. Viral
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protein of the avian anemia VP3/Apoptin has a positively
charged C-terminus that is reported to induce apoptosis
selectively on transformed and tumor cells, leaving nor-
mal cells intact [12, 13]. VP3 in the murine tumor model
was shown to be anti-tumorigenic, mostly through in-
duction of apoptosis [14, 15]. The ability of VP3 in indu-
cing p53-independent apoptosis has been demonstrated
in more than 70 tumor cell lines [16]. Although simul-
taneous VP3, interleukin-24 [17], interleukin-18 [18],
upregulations and survivin downregulation [19] seemed
to show greater anti-tumor activity than VP3 alone, the
combined effect of VP3 and shRNA on CD147 affecting
tumor growth and progression is yet to be investigated.
In this study the combined effect of pVIVO1-GFP/VP3
and psiRNA-CD147/2 was examined in the attempt




Female, 5 to 6 week-old BALB/c mice were obtained
from Institute Medical Research (IMR, Malaysia) and
were acclimatized for a week prior to use. All mice were
kept in individually ventilated cages (IVC) with constant
rotation rate of 70 air-changes/h. Mice were fed on ster-
ilized commercial diet, given water ad libitum and sub-
jected to 12 h light and dark cycle. The study was
performed with approval of the Institutional Animal
Care and Use Committee, Universiti Putra Malaysia
(UPM/FPV/PS/3.2.1551/AUP-R103).
Tumor cells
Murine CT26 colon cancer cell lines (ATCC® CRL-2638™)
was purchased from American Type Culture Collection
(ATCC) and cultured in RPMI 1640 medium (Gibco,
USA) supplemented with 10 % heat inactivated fetal
bovine serum (FBS) (Gibco, USA) and 1 % Penicillin/
Streptomycin antibiotic solution (Gibco, USA).
Plasmid DNA
The psiRNA-CD147/2 was constructed by cloning short
hairpin RNA (shRNA) specifically targeting mouse CD147
mRNA (GenBank: NM_001077184) into the eukaryotic
expression vector, psiRNA-h7SKzeo (InvivoGen, USA)
equipped with h7SK promoter region. shCD147/2 nu-




3’ and antisense 5’-AGCTTTTCCAAAAAGGCAATCAC-
CAA TAGCACTGACTCTTGATCAGTGCTATTGGT-
GATTGCCGAG-3’. The oligonucleotides were annealed
and cloned into Acc 65I and HindIII sites of the vector ac-
cording to manufacturer’s instruction. The construction of
plasmid pVIVO1-GFP/VP3 was described previously [20].
Briefly, pVIVO1-GFP/VP3 contains VP3 gene under the
control of CMV enhancer and GRP78 promoter region.
VP3 gene was synthesized from a local Chicken Anaemia
Virus isolate (GenBank: AF_030518). The unmodified
psiRNA-h7SKzeo and pVIVO1-GFP/LacZ were used as
controls treatment. All plasmids DNA used were purified
with Qiagen columns (Qiagen, Germany) using
endotoxin-free reagents according to the manufacturer’s
protocol. Plasmid DNA was diluted in sterile PBS, left at
room temperature for 10 min prior to intratumoral
injection.
Animal colon cancer model
The mice were anesthetized with 40 mg ketamin plus
8 mg xylazine/kg bwt intraperitoneally and placed on
37 °C warming pad. Cell suspension containing 1 × 106
CT26 cells in 0.2 mL sterile PBS were subcutaneously
injected on the right flank of the mice with minimal
trauma. The mice were observed on alternate days for
tumor development and palpable tumors were measured.
Treatments of the mice were instituted when the tumors
reached sizes of approximately 50 mm3 or ≥200 mm3.
Each control and treatment group comprise of 3 mice.
Measurement of tumor growth and evaluation of
antitumoral effect
Tumor volume was determined by measuring the greatest
length and width using calipers, and calculated by using
the following formula [21]:
Tumor volume Vð Þ ¼ length  width2 =2
Evaluation of antitumoral effect was determined ac-
cording to Sanceau J. et al. [22]. Individually relative
tumor volume (RTV) was defined as follows:
Relative tumor volume RTVð Þ ¼ Vx=V1
where Vx is the volume (mm
3) at a specific time and V1
is the volume at the beginning of treatment. Treatment
efficacy was expressed as the percentage of tumor
growth inhibition (TGI) as follows:
TGI %ð Þ ¼ 100‐ T=C  100ð Þ
where T and C is the mean RTV of treated and control
group at the time of sacrifice, respectively. Tumor
growth delay (TGD) was determined as the time re-
quired for the tumor volume to reach 10-fold over the
initial volume. Tumor growth delay index (TGDI) was
calculated as follows:
TGDI ¼ TGDT=TGDC
where TGDT and TGDC is the mean TGD of the treated
and control group, respectively.
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Experimental design
Protocol I: Individual treatment
When the tumors reached volumes of 45 to 50 mm3,
each mouse was treated intratumorally with 100 μg of
treatment in 70 μl of sterile PBS. Three doses of treat-
ment were injected at alternate days into established
CT26-tumors according to the following regimens: (a)
Control group (mock treatment) - 100 μg of either
pVIVO1-GFP/LacZ (LacZ) or psiRNA-h7SKzeo (zeo),
(b) Treatment 1: 100 μg pVIVO1-GFP/VP3 (VP3), (c)
Treatment 2: 100 μg psiRNA-CD147/2 (shCD147/2).
Tumors growth were measured on alternate days for
20 days post-treatment.
Protocol II: Combination treatment
Mice with tumor size of ≥200 mm3 were treated intratu-
morally with 100 μg of treatment in 70 μl of sterile PBS
according to the following regimens: Control groups
were either a) non-treated, b) received 3 doses of 100 μg
pVIVO1-GFP/LacZ or c) 3 doses of 100 μg psiRNA-
h7SKzeo. Treatment mice received either a) 3 doses of
100 μg of pVIVO1-GFP/VP3 or b) 3 doses of 100 μg of
psiRNA-CD147/2. In combination therapy, mice re-
ceived either a) 3 doses of 50 μg of pVIVO1-GFP/VP3 in
combination with 3 doses of 50 μg of psiRNA-CD147/2
or b) 3 doses of 100 μg of pVIVO1-GFP/VP3 in combin-
ation with 3 doses of 100 μg of psiRNA-CD147/2, repre-
senting low and high dose treatments, respectively. In
combination study, mice received pVIVO1-GFP/VP3
and psiRNA-CD147/2 treatments alternately, while in
control and single treatment, mice received doses at al-
ternate days. Tumor growth was examined on alternate
days for 25 days post-treatment.
Blood was collected from all mice prior to sacrifice
and tumor tissues were fixed either in 10 % neutral buff-
ered formalin for hematoxylin and eosin staining and
immunohistochemical analysis or flash-frozen in liquid
nitrogen and stored at -80 °C for molecular analysis. The
serum creatinine, blood urea nitrogen (BUN), alkaline
phosphatase (ALP), alanine transaminase (ALT) and as-
partate transaminase (AST) were determined spectro-
phometrically using standard commercial kits (Roche,
Swizerland).
DNA fragmentation analysis
In this analysis the genomic DNA (gDNA) from frozen
tumor tissues were isolated using DNAzol (Molecular
Research Centre, Inc, USA) in accordance with manu-
facturer’s protocol. Briefly, 50 mg of tumor tissue was
rinsed with PBS. DNAzol-tumor tissue homogenization
was performed using pre-cleaned pestle and mortar.
The homogenate was then centrifuged for 10 min at
10 000 × g to sediment the remaining insoluble
tissues. Thereafter, the viscous supernatant was
transferred to new microcentrifuge tube and apoptotic
DNA fragments were precipitated using 100 % absolute
ethanol at 6 000 × g for 6 min. After centrifugation, the
DNA pellet was rinsed 2 times with 70 % ethanol by
inverting a few times and sediment at 1000 × g for
1 min. Finally, DNA pellet was air dried and resus-
pended in sterile dH2O. DNA fragmentation was deter-
mined by 2 % agarose gel electroporation in 1 × TBE
buffer and run at 80 V for 45 min. The DNA was stained
with ethidium bromide and visualized under UV transil-
luminator. Apoptotic cells were appeared as a ladder
pattern while necrotic as a smear pattern on the gel. In-
tact genomic DNA appeared as a band at the top of the
lane.
Terminal deoxynucleotidyl transferase-mediated nick
end-labeling assay
Apoptotic endonucleases cleave DNA to produce frag-
ments with 3’-OH groups that can be detected on tumor
sections stained with FragEL DNA Fragmentation De-
tection Kit-Klenow Enzyme (Calbiochem, USA) and re-
corded digitally using light microscopy (Nikon Elipse
TE2000-S, Nikon, Japan) at × 200 magnification. Ap-
proximately, 5–10 random images were taken for each
group (n = 3). Briefly, fixed tumor tissues were dehy-
drated, cleared, infiltrated and paraffin embedded. Tissue
sections of 4 μm were prepared using rotary microtome
and mounted onto glass slides, deparaffinized, rehy-
drated and treated according to manufacturer’s proced-
ure. Apoptosis was determined by stained nuclei with
brown color after labelled with DAB. Tumor sections
were counterstained with methyl green. TUNEL-positive
cells were counted and analyzed using Image J software
(ImageJ 1.43u, USA), and the apoptotic index (AI) was
calculated as percentage of TUNEL-positive cells per
total number of cells.
Flow cytometry
To further ascertain that the treatment caused tumor
cell death through apoptosis rather than necrosis, the
tumor cells were subjected to flow cytometry after stain-
ing with annexin V-FITC and propidium iodide. The
technique allows for differentiation between living,
apoptotic, and necrotic cells. Apoptotic cells were fur-
ther differentiated into those in early and late apoptosis.
This method detects the translocation of the negatively
charged phospholipid phosphatidylserine (PS) on cell
membrane surface during the early stages of apoptosis.
Single cell suspensions were subjected to flow cytometry
following Annexin V-FITC and propidium iodide (PI)
staining using the ApopNexin™ FITC Apoptosis Detec-
tion Kit (Chemicon, USA). For single cell preparation,
tumor tissues were placed on sterile petri dish and
washed 3 times with PBS. Tumor tissues were cut into
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small pieces (1–2 mm3 in size) and then carefully disin-
tegrated with fine forceps in 2 ml of PBS. Cells were
then transferred into a 15 ml conical centrifuge tube and
resuspended gently and rapidly in 10 ml of ice-cold PBS.
The cells suspension was then centrifuged at 170 × g for
1 min (4 °C) to sediment the remaining tissue fragments.
The supernatant containing single cells was transferred
into a new 15 ml conical centrifuge tube and centrifuged
at 170 × g for 10 min. The supernatant was discarded
and pellet was resuspended in ice-cold PBS at a concen-
tration of 1 × 106 cells/mL and kept on ice. Then, tumor
cells suspensions were centrifuged to remove PBS and
resuspended in ice-cold 1× Binding Buffer (10 mM
Hepes/NaOH; pH 7.4, 140 mM NaCl and 2.5 mM
CaCl2) at 1 × 10
6 cells/mL. 200 μL of cells suspension
were aliquoted in polystyrene round-bottom tube and
stained with 3 μL of Annexin V-FITC. 2 μL of 100× PI
solutions were added to the Annexin V-FITC-labelled
cells and the suspension incubated at room temperature
in the dark for 15 min and analyzed immediately using
the Becton Dickinson FACS Calibur equipped with Cell-
Quest Pro software. Cells labelled as FITC+/PI− are in
early apoptosis; cells labelled as FITC−/PI+ are necrotic
or broken; cells labelled as FITC+/PI+ are either in late
apoptosis or secondary necrosis; and cells negatively la-
belled as FITC−/PI− are viable.
Statistical analysis
The results are expressed as mean ± standard error of
the mean. The data were analyzed by either Student’s
paired t-test or ANOVA followed by Tukey multiple
comparison post hoc test. The P value of <0.05 was con-
sidered significant.
Results
Colon cancer mice model
A small tumor mass of 48.41 ± 1.28 mm3 was palpable at
day 10 day post-implantation. The tumor was allowed to
grow achieving a size of 210.9 ± 7.26 mm3 by 15 days
post-implantation.
Complete regression by VP3 or shCD147/2 treatment in
small size tumor
In mice with tumor size approximately 50 mm3, VP3 as
well as shCD147/2 treatments showed regression in
tumor volume from 47.0 ± 3.5 and 48.4 ± 2.2 mm3 before
treatment to 7.1 ± 1.1 and 31.1 ± 7.5 mm3 on the day 7
post-treatment, respectively (Fig. 1). By that time the
tumor volume in untreated control mice increased to
336.5 ± 9.2 mm3 and continued to increase rapidly
reaching a volume of 4 000 mm3 by day 20. In mice
treated with either VP3 or shCD147/2, the tumor
remained smaller than 50 mm3 and finally regressed
completely by day 30 post-treatment.
VP3-shCD147/2 combination treatment increased tumor
growth delay index (TGDI)
In mice with tumor size of ≥200 mm3, both low and
high dose VP3 plus shCD147/2 combination treatments
caused more significant (p < 0.05) antitumor effects than
either VP3 or shCD147/2 alone (Fig. 2). In combination
treatments, the tumor size decreased from the initial size
of 200.9 ± 14.2 and 211.3 ± 16.6 mm3 to 150.3 ± 25.1 and
166.1 ± 24.6 mm3 on day 3 post-treatment for low and
high dose, respectively. Treatments with either VP3 or
shCD147/2 did not reduce tumor size, on day 3. In fact
the tumor increased slightly in size from 216.5 ± 13.8 to
Fig. 1 Development and treatment of CT26 colon cancer in mice. The tumors were treated with VP3 or shCD147/2 and tumor volume was
determined on alternate day for 20 days. The treatments effectively suppressed tumor growth. Inset depicting zoom-in of days 1-7
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226.4 ± 24.0 mm3 and 200.3 ± 10.4 to 274.3 ± 48.3 mm3
for VP3 and shCD147/2 treatment, respectively.
Relative tumor volume, which is the size of tumor at a
given time compared with the initial size, is shown in
Fig. 3. The growth began slowly and began to accelerate
from approximately 12 days post-treatment. However, in
untreated mice the tumor grew rapidly reaching much
higher relative volume than in treated mice at day 25
post-treatment. Tumors treated with VP3, shCD147/2,
low and high dose combination undergo 40.0, 45.2, 51.1
and 60.3 % of growth inhibition, respectively. TGDI, in-
dicating treatment efficiency is calculated as the delay
in days taken by the treated tumors to reach a 10-fold
RTV divided by the delay in the control group. The
TGDI of tumors treated with VP3, shCD147/2, low and
high dose combination treatments increased by 1.3-,
1.2-, 2.0- and 2.3-fold respectively, from the initial vol-
ume. Thus, the results showed that combination VP3
and shCD147/2 treatments were more effective than
VP3 or shCD147/2 alone.
Fig. 2 Representative photographs of tumors taken at day-1 before treatment and day-3 after treatment. CUT = Untreated control, CLacZ = pVIVO1-GFP/LacZ
control, Czeo = psiRNA-h7SKzeo control, TVP3 = Treated with pVIVO1-GFP/VP3 (VP3), TshCD = Treated with psiRNA-CD147/2 (shCD147/2), TV-shCD(50)
and TV-shCD(100) = Treated with low and high dose of VP3-shCD147/2 combination respectively. Circles show significantly size reduction in
combinative treatment
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Biochemical analysis of colon cancer mice model after
treatment
Serum liver enzymes and kidney function parameter
concentrations were estimated to determine safety of
plasmids pVIVO1-GFP/VP3 (VP3) and psiRNA-CD147/
2 (shCD147/2) as therapeutic compounds. Except for
AST, neither liver enzymes nor kidney function parame-
ters showed significant (p > 0.05) difference between
treatments and untreated control (Fig. 4). However,
AST, which in this case reflects muscle integrity were
significantly (p < 0.05) higher in mice tumor treated with
LacZ and zeo.
VP3 overexpression and knockdown of CD147 induced a
cellular morphologic change in CT26 tumor cells
Under H&E staining, tumor tissues in all mice treated
with VP3, shCD147/2 or their combination showed typ-
ical features of apoptosis to include interstitial spaces,
apoptotic bodies, and dark nuclei. In contrast, control,
LacZ- and zeo-treated mice did not show similar cellular
morphology. Tumor of treated mice also showed fewer
mitotic events than those of the controls. Tissue section
from tumors treated with shCD147/2 also showed nu-
merous blood vessel ruptures (Fig. 5).
VP3, shCD147/2 and combinations treated tumors
characterized by DNA laddering
Treatment with VP3, shCD147/2 or their combination
at 72 h post-treatment lead to high intensity laddering
indicating apoptotic activity (Fig. 6). This observation
was most obvious in tumors treated with 100 μg VP3-
shCD147/2 combination. The gels from untreated con-
trol, LacZ- and zeo-treated tumors showed smeared
bands suggesting complete DNA lysis indicating
necrosis.
Enhanced apoptotic events in VP3-shCD147/2
combination treated tumors
Apoptotic endonucleases cleave nuclear DNA to pro-
duce fragments with 3’-OH groups that can be detected
on tumor sections. Apoptotic cells were observed as
dark brown nuclear staining while viable cells stained
green color (Additional file 1: Figure S1). Tumors
treated with VP3, shCD147/2 and their combinations
showed numerous TUNEL-positive cells indicating
apoptosis (Fig. 7a). There were more than 60 % apop-
tosis in the treated tumors compared to <1 % in the un-
treated and control tumors. The apoptotic index (AI) of
tumors treated with VP3 and shCD147/2 were 63.9 ± 4.0
and 62.1 ± 4.2 % respectively, while in the 50 and 100 μg
VP3-shCD147/2 combination treatments, the AI was
74.7 ± 0.4 and 92.1 ± 3.5 % respectively (Fig. 7b).
VP3-shCD147/2 combination treatment increased the rate
of apoptosis in CT26 tumor cells
Figure 8a, b shows proportion in percentage of live vi-
able, necrotic, early apoptotic and late apoptotic cells in
untreated, control LacZ, control zeo, VP3, shCD147/2,
50 and 100 μg combination treated tumor at day-3 and
day-25 respectively. The rate of apoptosis in mice tumor
treated with shCD147/2 on day 3 post-treatment was
89.59 ± 5.85 %, while in tumors treated with VP3, 50
and 100 μg combination treatments were 60.10 ± 3.98,
28.62 ± 0.47 and 39.05 ± 0.56 %, respectively (Fig. 8c).
The rate of apoptosis in VP3-treated tumors remained
constant till day 25 post-treatment. In shCD147/2-treated
Fig. 3 Relative tumor volumes in mice CT26 colon cancer cell line-induced tumor treated with LacZ, zeo, VP3, shCD147/2 and VP3-shCD147/2
combination. On long-term, combination VP3-shCD147/2 treatments were effective in inhibiting tumor growth than either VP3 or
shCD147/2 alone. The plasmids used in the treatments were pVIVO1-GFP/LacZ (LacZ), psiRNA-h7SKzeo (zeo), pVIVO1-GFP/VP3 (VP3) and
psiRNA-CD147/2 (shCD147/2)
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tumors the rate of apoptosis decreased to 52.07 ±
2.65 % and in 50 and 100 μg combination treatments
the apoptosis rate increased to 83.14 ± 0.99 and 89.51
± 0.56 %, respectively (Fig. 8d).
Discussion
In this study, transfection of colorectal tumors with VP3
gene in combination with psiRNA-CD147/2-induced
CD147 silence as cancer gene therapy for colorectal can-
cers in the CT26 colorectal cancer cell-induced mouse
model was investigated. The CT26 cell line is a rapid-
growing grade IV carcinoma that can readily undergo
metastasis [23]. For that reason, the CT26 mouse tumor
is one of the most extensively used model in the investi-
gation of colorectal carcinomas [24]. Intra-tumoral
administration of pVIVO1-GFP/VP3 was shown to cause
significant reductions in tumor size in these mice [25, 26].
The viral-vectored VP3 has also been shown to cause
regression and complete remission of the xenograft of
human hepatomas grown in mice [27].
To determine the therapeutic effect of VP3 protein on
CT26 tumors, a sustainable and tumor-inducible GRP-
promoter was used to enhance the VP3 expression in a
targeted cell population [28–30]. When the tumor was
treated with recombinant pVIVO1-GFP/VP3 there was
complete regression of tumor showing that recombinant
plasmids harboring VP3 can be anti-tumorigenic. Partial
regression of CT26 tumors can be induced by CD147
silencing as shown in mice with human colon cancer
xenograft [31] and can be achieved with psiRNA-
Fig. 4 Serum liver enzymes and kidney function parameters in treated mice with CT26 colon cancer cell-induced tumor. a Liver enzymes;
ALT = alanine transaminase, ALP = alkaline phosphatase, AST = aspartate transaminase and b kidney function parameters; creatinine and urea. Data
are mean ± SEM. *P < 0.05 compared to the untreated group. UT = Untreated control, LacZ = pVIVO1-GFP/LacZ, zeo = psiRNA-h7SKzeo,
VP3 = pVIVO1-GFP/VP3 and shCD147/2 = psiRNA-CD147/2
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CD147/2. Although pVIVO1-GFP/VP3 and psiRNA-
CD147/2 are both effective antitumor agents, our study
showed that pVIVO1-GFP/VP3 is superior to psiRNA-
CD147/2. Further, when pVIVO1-GFP/VP3 was used in
combination with psiRNA-CD147/2, the antitumor ef-
fect was enhanced. This observation suggests that
pVIVO1-GFP/VP3 and psiRNA-CD147/2 act synergis-
tically in causing tumor regression. It is proposed that
the synergistic effect is attributed to the tumor CD147
silencing causing inhibition of tumor cell proliferation
and invasion, and proapoptotic VP3 gene transfected
into the tumor cells through the use of pVIVO1-GFP/
VP3 [32].
Induction of apoptosis is the mode of cell death targeted
by most antitumor agents. Treatments with pVIVO1-
GFP/VP3, psiRNA-CD147/2 and their combination were
Fig. 5 Histopathology of CT26 colon cancer cell line-induced tumor in mice. CUT = Untreated control, CLacZ = pVIVO1-GFP/LacZ control,
Czeo = psiRNA-h7SKzeo control, TVP3 = Treated with pVIVO1-GFP/VP3 (VP3), TshCD = Treated with psiRNA-CD147/2 (shCD147/2), TV-shCD(50) and
TV-shCD(100) = Treated with low and high dose of VP3-shCD147/2 combination respectively. Tumors were resected at day 25 post-treatment. Sections
showing numerous mitotic features (arrow heads), extensive fibrosis (fi border by a dotted line), blood vessel ruptures (asterisk) and numerous
apoptotic bodies (full arrows). H&E (×200). Right panel of TV-shCD(100) at × 400 magnification
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shown to cause apoptosis of CT26 mouse tumor cells.
The antitumor effect of pVIVO1-GFP/VP3 and psiRNA-
CD147/2 was rapid and remained constant for the period
of the study in the case of pVIVO1-GFP/VP3 treatment
or eventually waned when psiRNA-CD147/2 was used.
When pVIVO1-GFP/VP3 and psiRNA-CD147/2 were ad-
ministered as combination treatment, apoptosis of tumor
cells was slow to occur; however, after 25 days the com-
bination in fact killed the majority of tumor cells. The
mode of tumor cell death was apoptosis and this was sup-
ported by histopathology, where tumor tissues showed
abundance of apoptotic features. On the contrary, there
was an abundance of mitotic features in the untreated and
control tumor tissue indicating rampant tumor growth.
One of the effects of psiRNA-CD147/2 is the triggering of
indirect endothelial damage in the tumor tissues causing
collapse of tumor vasculature. The net effect is poor blood
flow and deprivation of oxygen supply to the tumors tis-
sue culminating in tumor cell death.
The effectiveness of tumor-treatment was also ascer-
tained by electrophoresis, TUNEL assay, and flow cy-
tometry analysis. Normally, apoptotic DNA cleavage
produced a signature pattern with high and low molecu-
lar weight fragments [33–35]. The presence of multiples
of 180 to 200 bp DNA fragments indicated that treat-
ment with pVIVO1-GFP/VP3, psiRNA-CD147/2 and
their combination had caused apoptosis of tumor cells.
CD147 knockdown eventually sensitized tumor cells to
anoikis, which is a form of apoptosis induced by the de-
tachment of anchorage-dependent cells from the sur-
rounding extracellular matrix [10, 36]. In this study, the
intensity of DNA ladder of the tumor cells treated with
pVIVO1-GFP/VP3 was equivalent to that produced by
those treated with psiRNA-CD147/2. However, the DNA
ladder intensity was higher in tumors treated with
pVIVO1-GFP/VP3-psiRNA-CD147/2 combination.
Another method used to assess for apoptosis is the in
situ terminal deoxynucleotidyl transferase biotin-dUTP
nick end labeling assays (TUNEL). The TUNEL assay
was purposely used to detect nuclear DNA fragmenta-
tion by identifying generation of nicks and breaks in the
DNA strands [37]. On the other hand, this assay was
used in quantifying and comparing the number of
TUNEL-positive cells between tumor samples; VP3-,
shCD147/2- and combination-treated. The highest ex-
tent of apoptosis indicate by AI was in tumors treated
with pVIVO1-GFP/VP3-psiRNA-CD147/2 combination
compared to tumors from VP3 or shCD147/2 treated
alone.
Flow cytometry analysis allowed the sensitive detection
of apoptotising cells. The apoptosis percentage in the
pVIVO1-GFP/VP3 treated tumor was sustained at day-3
and day-25 due to the GRP promoter sustainable effect.
Meanwhile, apoptosis percentage in the psiRNA-CD147/
2 treated tumor was high at day-3 and then declining at
day-25 because vasculature rupture at the first few days
causes anoikis which is interpreted as late-apoptosis;
however the treatment becomes less effective with time.
The apoptosis percentage in the combinatively pVIVO1-
GFP/VP3-psiRNA-CD147/2 treated tumor was markedly
increased compared to individually treated samples at
day-25 post-treatment. The effects of shCD147/2 are
triggering indirect damage to the pre-existing tumoral
endothelium, results in collapse of the vasculature inside
Fig. 6 DNA fragmentation on 2.0 % agarose gel. Lanes M: DNA marker (NEB, USA); CUT = Untreated control, CLacZ = pVIVO1-GFP/LacZ control,
Czeo = psiRNA-h7SKzeo control, TVP3 = Treated with pVIVO1-GFP/VP3 (VP3), TshCD = Treated with psiRNA-CD147/2 (shCD147/2), TV-shCD(50) and
TV-shCD(100) = Treated with low and high dose of VP3-shCD147/2 combination respectively. Open arrow heads showing the laddering pattern
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solid tumors. Thus, the tumor cells is deprived of oxygen
supply or blocked from blood flow, which consequently
leads to enhancement of pro-apoptosis induction by
pVIVO1-GFP/VP3. The pVIVO1-GFP/VP3-psiRNA-
CD147/2 combination treatment seemed to synergise
the effects of pVIVO1-GFP/VP3 and psiRNA-CD147/2
by intensifying antitumor effect in prolonged treatment.
Tumor growth is exponential in the early stages, then be-
comes less aggressive, and plateaus at the late stages of the
disease [38]. Since psiRNA-CD147/2 is very effective early
and pVIVO1-GFP/VP3 has a consistent effect throughout
tumor development, the pVIVO1-GFP/VP3-psiRNA-
CD147/2 combination treatment would be the more effi-
cacious antitumor regimen than either pVIVO1-GFP/VP3
or psiRNA-CD147/2 alone.
Chemotherapy is plagued with side-effects, thus new
drugs or therapeutic regimens require toxicity testing. In
this study, the effect of pVIVO1-GFP/VP3, psiRNA-CD147/
2 and their combination on the liver and kidneys were
ascertained by determining serum ALT, ALP, AST, urea and
creatinine concentrations. With the exception of slightly ele-
vated AST concentration, all blood biochemical parameters
were normal indicating that the liver and kidneys were not
affected by the treatments. Increase in AST may be associ-
ated with some muscle damage or increased muscular activ-
ities that are not associated with the toxic effect of the
treatments. Thus, pVIVO1-GFP/VP3, psiRNA-CD147/2
or their combination is generally nontoxic and safe to be
in mice, but proper Pharmacokinetics (PK) analyses are
required to confirm prior to clinical work in humans.
Fig. 7 Apoptosis in treated mice CT26 colon cancer cell-induced tumor determined by TUNEL assay at day 25 post-treatment. a Tumor tissue
with nick-labeling fragmented DNA. Apoptotic cells are stained dark brown while viable cells stained green color, 200×. Magnifying: shows brownish
to darkish labeled nuclear granules. b Apoptotic index of tumor tissue. Error bars represent the standard error of the mean. Means with different letters
are significantly (p < 0.05) different. CUT = Untreated control, CLacZ = pVIVO1-GFP/LacZ control, Czeo = psiRNA-h7SKzeo control, TVP3 = Treated
with pVIVO1-GFP/VP3 (VP3), TshCD = Treated with psiRNA-CD147/2 (shCD147/2), TV-shCD(50) and TV-shCD(100) = Treated with 50 and 100 μg dose of
VP3-shCD147/2 combination respectively
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Conclusions
The antitumor effect of the combination treatment is
the result of synergistic effects of VP3 and shCD147/
2 on the tumor cells resulting in apoptosis. Based on
these studies, we conclude that the pVIVO1-GFP/
VP3-psiRNA-CD147/2 combination therapy is poten-
tially effective and safe regimen for treating colorec-
tal cancers.
Fig. 8 Apoptosis in treated mice CT26 colon cancer cell-induced tumor determined by fluorescence-activated cell sorting. Tumor cells were
labeled with FITC-annexin V and propidium iodide at a day 3 post-treatment and b day 25 post-treatment. Histogram showed quantification of
apoptosis in treated tumors at c day 3 post-treatment and d day 25 post-treatment. CUT = Untreated control, CLacZ = pVIVO1-GFP/LacZ control,
Czeo = psiRNA-h7SKzeo control, TVP3 = Treated with pVIVO1-GFP/VP3 (VP3), TshCD = Treated with psiRNA-CD147/2 (shCD147/2), TV-shCD(50) and
TV-shCD(100) = Treated with 50 and 100 μg dose of VP3-shCD147/2 combination respectively
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Additional file
Additional file 1: Figure S1. Morphological and histological features of
CT26 tumor. A) Exposed CT26-induced tumor becoming a spheroid
measuring 2–2.5 cm in diameter at day 25 post-treatment. The tumor
mass is well-defined and vascularized. Right panel, cross section of the
tumor. B) Photomicrographs of H&E-stained tumor sections. The tumor
was dissected at day 25 post-treatment for histological analysis. Top,
peripheral region showing intact tumor cells, and, bottom, inner region
showing tumor cells and a necrotic core. 100× magnification. C) TUNEL
assay were evaluated on CT26 tumor sections. Apoptotic cells indicate by
TUNEL-positive are stained dark brown while viable cells stained green
color. Top, peripheral region showing intact tumor cells and apoptotic
cells, and, bottom, inner region showing apoptotic cells, viable tumor cells
and a necrotic core. 100× magnification. (TIF 636 kb) (TIF 635 kb)
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